• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gemini Therapeutics, Inc. - Common Stock (NQ:GMTX)

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Dec 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gemini Therapeutics, Inc. - Common Stock

News headline image
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation
February 21, 2023
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
GEMINI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. - GMTX
August 12, 2022
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
GMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to Shareholders
August 10, 2022
From Halper Sadeh LLP
Via Business Wire
News headline image
Gemini Therapeutics and Disc Medicine Announce Merger Agreement
August 10, 2022
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Provides Corporate Update
February 28, 2022
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Provides GEM103 Program Update
January 10, 2022
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 15, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Poster Presentation at AAO 2021
November 12, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics to Participate in Upcoming Investor Conferences
November 11, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit
October 19, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 14, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy
October 05, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics
September 10, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual
September 09, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit
August 30, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference
August 10, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
June 22, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
May 26, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 13, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy
May 13, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors
May 03, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 01, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
April 13, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
News headline image
Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer
April 12, 2021
From Gemini Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap